-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651.O3.3 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational II

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Translational Research, genomics, bioinformatics, Plasma Cell Disorders, Diseases, immune mechanism, Gene Therapy, Therapies, Immunotherapy, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, molecular biology, Study Population, profiling, Human, omics technologies
Saturday, December 10, 2022: 2:00 PM-3:30 PM
R06-R09 (Ernest N. Morial Convention Center)
Moderators:
Arun P Wiita, MD, PhD, UCSF and Paola Neri, MD, PhD, University of Calgary
Disclosures:
Neri: Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Sanofi-Aventis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria.
2:00 PM

Keiji Kurata1*, Mehmet K. Samur, PhD2, Priscilla Liow3*, Kenneth Wen4*, Leona Yamamoto, MD5, Jiye Liu, PhD6*, Eugenio Morelli, MD7, Annamaria Gulla, MD8, Yu-Tzu Tai, PhD4, Jun Qi, PhD9*, Teru Hideshima, MD, PhD10 and Kenneth C. Anderson, MD3

1Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
3Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA
6The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
8Medical Oncology, Dana Farber Cancer Institute, Boston, MA
9Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston

2:15 PM

Travis S Johnson, PhD1,2, Parvathi Sudha, MS3*, Enze Liu, PhD3*, Vivek S. Chopra, PhD4*, Cedric E. Dos Santos, PhD4, Michael Nixon, MSN, MPH5*, Kun Huang, PhD1,2*, Rafat Abonour, MD3, Mohammad Issam Abu Zaid, MBBS3 and Brian A. Walker, PhD3

1Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN
2Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN
3Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
4Genentech, Inc., San Francisco, CA
5Genentech, Inc., South San Francisco, CA

2:30 PM

Sarah A. Bird, BMBCh1,2, Amy Barber, PhD1*, Fernando J. Sialana, PhD1*, Marco P. Licciardello, PhD1*, Harvey Che, PhD1*, Habib Bouguenina, PhD1*, Yura Grabovska, PhD1*, Enze Liu, PhD3*, Yakinthi Chrisochoidou, PhD1*, Shannon Martin, MRes1*, Jyoti Choudhary, PhD1*, Brian A. Walker, PhD3, Ian Collins, PhD1*, Paul Clarke, PhD1* and Charlotte Pawlyn, PhD1,2

1The Institute of Cancer Research, London, United Kingdom
2The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
3Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN

2:45 PM

Elizabeth D. Lightbody, PhD1,2,3, Danielle T. Firer, BS3*, Romanos Sklavenitis-Pistofidis, MD1,2,3, Junko Tsuji, PhD3*, Michael P. Agius, PhD1,2,3*, Ankit K. Dutta, PhD1,2,3*, Ting Wu, MS3*, Hadley Barr, BA1,2*, Mahshid Rahmat, PhD1,2,3*, Yoshinobu Konishi, MD, PhD1,3,4*, Michelle P. Aranha, PhD1,2,3*, Michael Vinyard, MSc3*, Jean-Baptiste Alberge, PhD1,2,5*, Nang Kham Su, MS2*, Cody J. Boehner, BS1,2*, Laura Hevenor, BS2*, Habib El-Khoury, MD1,2, Katherine Towle, BS2*, Christian J. Cea-Curry, BS1,2*, Erica Horowitz, BA2*, Jacqueline Perry, MPH1,2*, Anna Cowan, BA2*, Anna V. Justis2*, Daniel Auclair, PhD6, Catherine R. Marinac, PhD2,7, Gad Getz, PhD1,5,8* and Irene Ghobrial, MD1,2,3

1Department of Medicine, Harvard Medical School, Boston, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
5Broad Institute of MIT and Harvard, Cambridge, MA
6Hematology R&D, AstraZeneca, Waltham, MA
7Harvard T.H. Chan School of Public Health, Boston, MA
8Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA

3:00 PM

Mirco Friedrich1,2*, Niklas Kehl1*, Simon Steiger3*, Tim Robin Wagner1*, Katharina Lindner1*, Michael Kilian, PhD1,4*, Julius Michel1*, Sebastian Uhrig, PhD1*, Raphael Lutz, MD2,5*, Nina Prokoph, PhD2,6*, Alexandra M Poos, PhD2*, Lukas John, MD2*, Lilli Sophie Sester, MD2*, Niels Weinhold, PhD2*, Stefan Fröhling, MD7,8, Edward W Green, PhD1,4*, Lukas Bunse, MD1,4*, Paola Neri, MD, PhD9,10, Nizar Jacques Bahlis, MD10, Karsten Rippe, PhD3*, Stefan Eichmüller, PhD1*, Carsten Müller-Tidow, MD2,7*, Hartmut Goldschmidt, MD2,7, Michael Platten, MD1,4,7* and Marc S Raab, MD1,2*

1German Cancer Research Center (DKFZ), Heidelberg, Germany
2Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
3Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany
4Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
5Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
6Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
7National Center for Tumor Diseases (NCT), Heidelberg, Germany
8Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
9Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
10Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

3:15 PM

Lisa Pfeuffer1,2*, Lisa Brandmeier, MSc1,2*, Nicole Beck1,2*, Katja Steiger3*, Clemens-Martin Wendtner4,5, Jürgen Ruland1,2,6,7* and Maike Buchner1,2*

1Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany
2TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany
3Institute of Pathology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
4Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany
5Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Munich, Germany
6German Cancer Research Center (DKFZ), Heidelberg, Germany
7German Cancer Consortium (DKTK), Munich Partner Site, Munich, Germany

*signifies non-member of ASH